Lilly(Eli) & Co

NYSE:LLY   3:59:59 PM EDT
141.77
-0.61 (-0.43%)
4:00:00 PM EDT: $142.00 +0.23 (+0.16%)
Products, Regulatory

Lilly Provides Comprehensive Update On Progress Of Sars-Cov-2 Neutralizing Antibody Programs

Published: 10/07/2020 12:47 GMT
Eli Lilly and Co (LLY) - Lilly Provides Comprehensive Update on Progress of Sars-cov-2 Neutralizing Antibody Programs.
Eli Lilly and Co - Submitted Request for Emergency Use Authorization (eua) for Monotherapy to U.S. Food and Drug Administration.
Eli Lilly and Co - New Data Show Combination Therapy Met Primary and Secondary Endpoints.
Eli Lilly and Co - Plan to Initiate a Large Open-label Pragmatic Study in Covid-19 Outpatients in October.
Eli Lilly and Co - Anticipates It Could Supply As Many As One Million Doses of 700 Mg Ly-cov555 Monotherapy in Q4 2020, With 100,000 Available in October.
Eli Lilly and Co - Combination Therapy Has Been Generally Well Tolerated With No Drug-related Serious Adverse Events.
Eli Lilly and Co - Announced Additional Details on Its Sars-cov-2 Neutralizing Antibody Programs.
Eli Lilly and Co - Treatment Emergent Adverse Events Were Comparable to Placebo for Both Ly-cov555 Monotherapy and Combination Therapy.
Eli Lilly and Co - With Respect to Supply of Combination Therapy, Lilly Anticipates It Will Have 50,000 Doses Available in Q4 2020.
Eli Lilly and Co - Supply of Combination Therapy Will Increase Substantially Beginning in Q1 2021.
Eli Lilly and Co - Supply of Combination Therapy Will Increase Substantially Beginning in Q1 2021.
Eli Lilly - Data From New Interim Analysis of Blaze-1 Trial Showed Combination Therapy With 2 Sars-cov-2 Neutralizing Antibodies Reduced Viral Load, Symptoms.